Quantum BioPharma Ltd. Licensee Unbuzzd Wellness Inc. Launches Capital Raise Campaign

Toronto, Ontario – July 31, 2025 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91), a biopharmaceutical company focused on developing innovative assets and biotech solutions, announced that its licensee, Unbuzzd Wellness Inc., has initiated a Regulation D 506(c) offering. The campaign aims to raise up to US$5.0 million to fund growth initiatives and pave the way for a potential initial public offering (IPO). Importantly, this capital raise will not dilute Quantum BioPharma shareholders, as the company maintains a 25% ownership stake in Unbuzzd through an anti-dilution provision until Unbuzzd reaches a $1 billion valuation.

Unbuzzd Wellness Inc., led by CEO John Duffy, former Vice President of Coca-Cola, and Board Co-Chair Gerry David, former CEO of Celsius Holdings, is known for its flagship product, unbuzzd™. This scientifically-proven beverage is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms. The company has partnered with MZ Digital and Dealmaker to facilitate the capital raise, accepting both traditional and cryptocurrency payments through ALT5 Pay’s platform.

Quantum BioPharma’s strategic involvement with Unbuzzd underscores its commitment to fostering growth within its portfolio of innovative health solutions. The capital raised through this offering will support Unbuzzd’s expansion efforts and further solidify its market position, potentially leading to an IPO in the future.

This development comes at a time when the financial markets are experiencing heightened speculative activity, with trends reminiscent of the dot-com bubble of 2000. Market observers have noted a surge in trading activities involving options, meme stocks, and cryptocurrencies, driven by a fear of missing out (FOMO) sentiment. Despite these broader market dynamics, Quantum BioPharma’s focused approach with Unbuzzd aims to leverage its unique product offering to achieve sustainable growth.

Quantum BioPharma Ltd. is listed on the Canadian National Stock Exchange, with a market capitalization of 95,917,185 CAD. As of July 29, 2025, the company’s close price was 31.5 CAD, with a 52-week high of 52 CAD on June 19, 2025, and a 52-week low of 3.9 CAD on December 19, 2024.